Vectus Biosystems Limited (VBS) AI Stock Analysis

• Market Cap: AU$3.95M
• Dividend Yield: N/A
• Average Volume (3M): 6.10K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.50
• Revenue Growth: N/A
• EPS Growth: 24.09%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 53,333,332
• 10 Day Avg. Volume: 12,702
• 30 Day Avg. Volume: 6,100
• PEG Ratio: 0.05
• Price to Book (P/B): -8.29
• Price to Sales (P/S): 4.45
• P/FCF Ratio: -2.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

Vectus Biosystems Limited's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, persistent losses, and financial instability. While technical analysis shows some short-term positive momentum, the negative valuation metrics further weigh down the score. The absence of earnings call data and corporate events leaves these areas unaddressed in the analysis.

Vectus Biosystems Limited Business Overview & Revenue Model

Company Description

Vectus Biosystems Limited (VBS) is an Australian biotechnology company specializing in the development of novel treatments for fibrosis and high blood pressure. The company's core focus is on creating small molecule drugs aimed at treating fibrotic diseases, which are conditions characterized by the thickening and scarring of connective tissue. Vectus Biosystems is committed to addressing unmet medical needs through its innovative research and development efforts, and its leading product candidate is VB0004, which targets the fibrosis and hypertension markets.

How the Company Makes Money

Vectus Biosystems Limited generates revenue primarily through the development and potential commercialization of its proprietary drug candidates. The company invests in extensive research and development to advance its product pipeline, with a key focus on VB0004. Revenue is expected to be derived from licensing agreements, partnerships with pharmaceutical companies, and potential sales of approved drugs. Strategic collaborations and partnerships play a significant role in funding Vectus' research initiatives and expanding its market reach. The company may also receive milestone payments and royalties from licensing its drug candidates to other entities as they progress through clinical trials and into commercialization.

Vectus Biosystems Limited Financial Statement Overview

Summary

Vectus Biosystems Limited is facing significant financial challenges, with declining revenues, persistent losses, and a weak balance sheet with negative equity. Cash flow issues further exacerbate the financial instability, indicating a need for strategic changes to improve financial health and sustainability.

Income Statement

Vectus Biosystems Limited has experienced a significant decline in revenue, with a revenue growth rate of -45.92% in the most recent year. The company has consistently reported negative net profit margins, indicating ongoing losses. Despite a high gross profit margin, the negative EBIT and EBITDA margins reflect operational inefficiencies and high costs relative to revenue.

Balance Sheet

The company's balance sheet shows a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is negative, reflecting more liabilities than equity. While the return on equity appears positive, it is due to negative equity, which is not a favorable sign. Overall, the balance sheet suggests financial distress and high leverage.

Cash Flow

Vectus Biosystems Limited has negative operating and free cash flows, indicating challenges in generating cash from operations. The free cash flow growth rate is negative, and the operating cash flow to net income ratio is less than one, suggesting inefficiencies in converting income into cash. The free cash flow to net income ratio is positive, but this is due to negative net income, which is not a positive indicator.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	478.18K	478.18K	1.14M	1.35M	1.30M	180.00
Gross Profit	478.18K	478.18K	1.14M	1.31M	1.28M	1.02M
EBITDA	-1.69M	-1.69M	-2.27M	-3.19M	-3.28M	-3.71M
Net Income	-1.78M	-1.78M	-2.34M	-3.45M	-3.99M	-3.86M
Balance Sheet
Total Assets	782.66K	782.66K	2.03M	4.63M	3.94M	6.98M
Cash, Cash Equivalents and Short-Term Investments	250.99K	250.99K	808.97K	2.95M	1.28M	5.78M
Total Debt	200.00K	200.00K	28.93K	70.21K	6.90M	8.68M
Total Liabilities	1.04M	1.04M	539.26K	1.11M	8.36M	9.88M
Stockholders Equity	-256.62K	-256.62K	1.49M	3.52M	-4.42M	-2.90M
Cash Flow
Free Cash Flow	-830.09K	-830.09K	-2.10M	-2.37M	-4.46M	-3.26M
Operating Cash Flow	-830.09K	-830.09K	-2.03M	-2.35M	-4.44M	-3.26M
Investing Cash Flow	101.03K	101.03K	-67.90K	-17.13K	-21.00K	0.00
Financing Cash Flow	171.07K	171.07K	-41.28K	4.04M	-34.55K	6.35M

Vectus Biosystems Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.07
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VBS, the sentiment is Positive. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.38 is Neutral, neither overbought nor oversold. The STOCH value of -1.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:VBS.

Vectus Biosystems Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1AD	46 Neutral	AU$4.61M	―	-628.72%	―	―	31.87%
VBS	44 Neutral	AU$3.95M	―	-289.05%	―	―	24.09%
HXL	40 Underperform	AU$2.17M	―	-28.49%	―	―	46.43%
BIT	36 Underperform	$6.64M	―	-184.73%	―	―	87.88%
ANR	27 Underperform	AU$3.96M	―	-205.70%	―	―	1.03%

Vectus Biosystems Limited Corporate Events

Vectus Biosystems Advances Commercialization of Fibrosis Treatments

Vectus Biosystems Limited has made significant progress in its commercialization efforts, particularly with its lead compound VB0004, which targets fibrosis and high blood pressure. The company is actively engaged in licensing discussions and exploring opportunities for faster approval in the Chinese market. Vectus has also reduced its operating costs and is focusing on potential licensing and collaborations to fund further clinical studies. The company is working on obtaining a research and development cash-back claim to support its financial position.

Vectus Biosystems Expands Share Issuance Under Employee Incentive Plan

Vectus Biosystems Limited has issued 55,019 new fully paid ordinary shares to an employee under its Employee Incentive Plan. This move reflects the company’s ongoing efforts to incentivize its workforce and align employee interests with corporate goals, potentially impacting its operational dynamics and stakeholder relations.

Vectus Biosystems Expands Capital with New Securities Issuance

Vectus Biosystems Limited has announced the issuance of 55,019 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure, potentially impacting its financial flexibility and market presence positively.

Vectus Biosystems Issues Unquoted Options to Employees

Vectus Biosystems Limited announced the issuance of 75,000 unquoted options as part of an employee incentive scheme. This move is likely aimed at retaining talent and aligning employee interests with company growth, potentially impacting the company’s operational dynamics and stakeholder relations positively.